NCT06043674
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06043674
Title A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Matthew S. Davids, MD
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.